Plasmid DNA manufacturing and analytics: INFOGRAPHIC

Cell & Gene Therapy Insights 2023; 9(3), 865


Published: 28 July

The rapid increase of the gene therapy pipeline and genetic vaccination for various infectious diseases requires large-scale production of high-quality plasmid DNA (pDNA). In gene therapy applications, pDNA is a starting material for cell transfection. However, producing sufficient quantities of pDNA can be a challenge. Therefore, it is essential to establish robust manufacturing and analytics processes to produce large quantities of pDNA.